Sign Up to like & get
recommendations!
0
Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.02.065
Abstract: Liver fibrosis occurs in most types of chronic liver diseases. The understanding of the pathogenesis of liver fibrosis has grown considerably, but the effective treatments are still lacking. Alogliptin, a classical Dipeptidyl peptidase-4 (DPP4) inhibitor…
read more here.
Keywords:
stellate cell;
fibrosis;
liver fibrosis;
alogliptin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2021.173991
Abstract: In the present study, we investigated the vasorelaxant effects of alogliptin, an oral antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor class, using phenylephrine (Phe)-induced pre-contracted aortic rings. Alogliptin induced vasorelaxation in a dose-dependent manner.…
read more here.
Keywords:
channel inhibitor;
inhibitor;
vasorelaxation;
alogliptin ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Vascular pharmacology"
DOI: 10.1016/j.vph.2018.11.003
Abstract: OBJECTIVE Perivascular adipose tissue (PVAT) regulates vascular function in a paracrine manner and the vasodilatory effect of PVAT on vessels is completely abolished in obesity. In addition, autophagy is required for maintaining biological function of…
read more here.
Keywords:
alogliptin;
endothelial function;
obese mice;
function ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of pharmacy practice"
DOI: 10.1177/08971900221108721
Abstract: Background: Dipeptidyl peptidase (DPP)-4 inhibitors are commonly used agents to treat type 2 diabetes mellitus (T2DM). Although generally well tolerated, stomatitis has been previously reported as an adverse event with sitagliptin and linagliptin. Stomatitis with…
read more here.
Keywords:
alogliptin;
event;
stomatitis;
report ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of pharmacy practice"
DOI: 10.1177/08971900221135656
Abstract: Background: In 2016, the FDA issued a warning for saxagliptin and alogliptin regarding an increased risk of heart failure (HF), potentially limiting the use of effective medications in type 2 diabetes. Current data and guideline…
read more here.
Keywords:
alogliptin;
heart failure;
type diabetes;
risk ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "BMC Medicine"
DOI: 10.1186/s12916-020-01616-8
Abstract: Background The EXAMINE trial tested the efficacy and safety of alogliptin, an inhibitor of dipeptidyl peptidase 4, compared with placebo in 5380 patients with type 2 diabetes and a recent acute coronary syndrome. Because alogliptin…
read more here.
Keywords:
alogliptin;
egfr;
patients type;
type diabetes ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14091867
Abstract: The aim of the study was to design injectable long-acting poly (lactide-co-glycolide) (PLGA)-based in situ gel implants (ISGI) loaded with the anti-diabetic alogliptin. Providing sustained therapeutic exposures and improving the pharmacological responses of alogliptin were…
read more here.
Keywords:
factorial design;
alogliptin;
alogliptin loaded;
situ gel ... See more keywords